The short answer

At the moment, Arthrosamid appears mainly to be a private, self-funded treatment in the UK rather than a standard NHS option. The clearest NHS-facing source is the Health Research Authority study page, which says that for conservative knee osteoarthritis care, "currently only steroid injections are available as part of NHS treatment", while Arthrosamid was being used in a clinical study rather than routine care.

That fits with NICE’s position: its project page says Arthrosamid for knee osteoarthritis was not selected for guidance development because there was "insufficient evidence". Separate UK provider information also describes Arthrosamid as self-funded rather than NHS-provided. This does not prove there are no local exceptions or one-off arrangements, but the sources reviewed do not show routine NHS commissioning at present.

Why routine NHS access looks limited

The key distinction is between standard NHS care and research access. On the Health Research Authority page for an NHS study, Arthrosamid is described within a trial setting, not as part of the usual treatment pathway for conservative knee osteoarthritis. The same page states that "currently only steroid injections are available as part of NHS treatment", and it also notes that recruitment to that listed study is now closed. That combination matters: a treatment being studied in an NHS setting is not the same as it being routinely offered across NHS services.

A second signal comes from NICE. Its project page for Arthrosamid in knee osteoarthritis records the topic as "Not selected" for guidance development and says it was "not eligible for Health Technology Evaluation guidance" because there was "insufficient evidence" at that stage. NICE does not directly decide every local treatment offer, but its guidance process is an important part of the wider commissioning picture in England.

Taken together, the reviewed material did not identify a national NHS treatment pathway or clear evidence of routine commissioning for Arthrosamid. That is not the same as proving it is unavailable in every NHS setting: local exceptions, discretionary funding, further studies, or later policy changes may still occur. It does, however, help explain why routine NHS access currently looks limited from the sources reviewed.

What NHS research access actually means

Seeing Arthrosamid linked to an NHS study does not mean it is part of ordinary NHS treatment. On the Health Research Authority listing for an Arthrosamid knee osteoarthritis study, the injection is presented as a research intervention, and the page states that recruitment to that study is now closed. In practical terms, research access usually depends on whether a study is open at a recruiting NHS site, whether that site is within travelling distance, and whether a person meets the trial’s inclusion and exclusion criteria.

Research activity can still be important. In a 12 September 2023 update, Arthrosamid’s manufacturer said a study at The Robert Jones and Agnes Hunt Orthopaedic Hospital NHS Foundation Trust was under way to assess clinical effectiveness in an NHS setting. That is useful context, but it points to evidence being built rather than a treatment already being routinely offered across the NHS. Some people may be able to enter a study at the right time and place; many others will not, simply because no local trial is recruiting or they do not fit the study rules.

What private access usually looks like

For people trying to work out the practical UK route now, the reviewed access sources point mainly to private assessment through clinics or private hospitals rather than a standard booked NHS pathway. One UK provider page describes Arthrosamid as self-funded, meaning the consultation, injection and follow-up are paid for privately. The same page says it is not routinely covered there by major insurers such as Bupa and AXA, so insurance cannot be assumed even in the private sector.

That picture is reinforced elsewhere in the market. A current Imperial Private Healthcare listing shows Arthrosamid knee injections being offered through a private hospital service in the UK, which supports the idea that access is available privately now. The manufacturer’s clinic finder also points towards treatment being delivered through clinics, with a searchable network of over 400 clinics worldwide. In practice, that means the usual route is likely to be a private consultation first, followed by discussion of suitability, availability and funding on a case-by-case basis rather than automatic insurer approval or routine NHS provision.

How to check what applies in your area

Because the reviewed sources do not show a single UK-wide NHS pathway for Arthrosamid, the most sensible next step is to check what applies locally. In knee osteoarthritis, a good starting point is an NHS GP, local musculoskeletal service or orthopaedic team. Useful questions include whether there is any local policy on Arthrosamid, whether an exceptional funding route exists, and whether any research study is open nearby.

When speaking to a private provider in the UK, keep the discussion focused on decision points rather than marketing claims. A short checklist is:

• Is Arthrosamid considered suitable for the stage of osteoarthritis in this knee?
• What published evidence supports its use for that pattern of symptoms?
• Are other injection options, such as steroid, hyaluronic acid or PRP, more appropriate in this case?
• What is included in the private pathway, from assessment to follow-up?

The current evidence reviewed is clearest for knee OA, so it is worth being cautious about assuming the same access route for a hip or any other joint. If a next step is needed, AMSK offers a way to check suitability or request an assessment without assuming that NHS access, private access or research access will be the same in every area.